Hikal announces successful development of Favipiravir Active Pharmaceutical ingredient and its intermediates

Novel coronavirus 2019 nCoV pcr diagnostics kit. This is RT-PCR kit to detect presence of 2019-nCoV or covid19 virus in clinical specimens. In vitro diagnostic test based on real-time PCR technology

MUMBAI, May 15: Hikal Limited, a leading manufacturer and supplier of API’s and intermediates globally on Friday announced the successful development of Favipiravir Active Pharmaceutical ingredient (API) and its intermediates.
Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co Ltd, Japan, a subsidiary of Fujifilm Corporation.
The company has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. It is in various stages of clinical trials in many countries as an experimental treatment of COVID-19, the company said in a filing with BSE.
The company is in discussion with potential partners to supply the API and its intermediates.
Hikal has developed this API in a record amount of time to make the product available for the treatment of COVID-19. This demonstrates Hikal’s commitment to support in the fight against COVID-19 virus and to provide high-quality medicines to its customers globally.
(UNI)